
























In 1977, Andrzej "Andrew" V. Schally won Nobel 
Prize in medicine for his research into peptide 
hormone production in the brain. He described the 
neurohormone GnRH and other releasing hormones 
(RH). As initially unexpected application, agonists and 
antagonists of these hormones have become 
investigational anti-cancer agents [1-3]. As further 
developments, Schally and coworkers described 
targeting gastrin releasing peptide receptors. Gastrin-
releasing peptide (GRP) is involved in cancer growth 
and GRP receptors are expressed in a variety of cancer 
cells and have limited distribution in normal human 
tissue. Thus inhibition of GRP receptors represents an 
attractive target for pharmacological treatment of 
certain human malignancies [4]. Also, MZ-5-156, an 
antagonist of growth hormone-releasing hormone 
(GHRH), decreased cell proliferation and activated 
AMPK and inhibited Akt, the mammalian target of 
rapamycin (mTOR) and its downstream target eIF4E 
which controls protein synthesis and cell growth [5]. 
GHRH antagonists also caused cell cycle arrest and 
apoptosis in human colon cancer cells [6, 7]. 
 
Yet, this is only one of hundreds examples for new 
therapeutic targets and new types of drugs that have 
been developed recently in cellular and animal models. 
Searche for new targets has continued with many 
promising lead compounds identified [8-38]. 
 
 
























Among promising targets are cancer stem cells [39-42], 
microRNAs [43-50], the MEK/ERK pathway [51-64] 
and especially its upstream activator BRAF [61, 65-67] 
and the NF-kB pathway [68], Myc and HIF-1 [69-72], 
The CtBP transcriptional corepressors [73], Polycomb 
group (PcG) proteins  [74], autophagy   [75-77], 
translation [78], the proteasome [35], HSP70 [79, 80], 
Hsp90 [81-84], the AMPK-FoxO3A axis [85], STAT3 
and MEK/ERK/BCL-2 signaling [86], the Hh signal 
transducer Smoothened [87], ErbBs receptor tyrosine 
kinases [88], and anti-apoptotic members of the Bcl-2 
family, Bcl-2, Bcl-X(L) and Mcl-1  [89]. Stromal and 
endothelial cells are also targets [90, 91]. There are also 
new targets for anti-angiogenic therapy [71, 75, 78, 92-
94]. Also, epithelial mesenchymal transition (EMT) is a 
critical mechanism for the acquisition of malignant 
phenotypes by epithelial cells [95]. In colorectal cancer, 
such cells are histologically represented by tumor buds 
defined as single cells or small clusters of de-
differentiated tumor cells at the invasive front. These 
buds are also considered as targets for novel cancer 
therapy [96, 97]. Recently, leukocytes in the ovarian 
cancer microenvironment such as regulatory T cells and 
immature pro-angiogenic myeloid cells have been 
demonstrated to play a fundamental role in tumor 
progression and have been suggested as potential target 
[98]. Cdk4/6 is an attractive target for cancer therapy. 
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hibitor, named Compound A potently inhibits Cdk4 and 
Cdk6 with high selectivity [99]. Among 82 human cell 
line examined, leukemia and lymphoma cell lines 
tended to be more sensitive to Compound A. In a nude 
rat xenograft model, Compound A inhibited cell 
proliferation in xenograft tumors at a plasma 
concentration of 510 nM. Compound A only moderately 
inhibited cell cycle progression of normal crypt cells in 
small intestine even at 5 times higher plasma 
concentration and did not cause immunosuppression 
even at 17 times higher concentration [99]. 
 
Targeting the androgen receptor also has also shown 
significant progress [100-103].  An interesting example 
is targeting androgen receptor in estrogen receptor-
negative breast cancer [104].  Also, a small-molecule 
inhibitor of the amino-terminus domain of the androgen 
receptor causes regression of castrate-recurrent prostate 
cancer   [105, 106]. Recent discoveries revealed a 
transcription-independent function of androgen receptor 
that is essential for prostate cancer cell viability and, 
therefore, is an ideal target for anticancer treatment. 
Several of the identified AR inhibitors demonstrated in 
vivo efficacy in mouse models of PCa and are 
candidates for pharmacologic optimization [107]. 
 
Among numerous new experimental therapeutics, a 
small-molecule inducer of polyploidy, R1530, interferes 
with tubulin polymerization, leads to abortive mitosis, 
endoreduplication and polyploidy. In the presence of 
R1530, polyploid cancer cells underwent apoptosis or 
became senescent which translated into potent in vitro 
and in vivo efficacy. Normal proliferating cells were 
resistant to R1530-induced polyploidy thus supporting 
the rationale for cancer therapy by induced polyploidy. 
BubR1 plays a key role in polyploidy induction by 
R1530 and could be exploited as a target for designing 
more specific polyploidy inducers [108]. Vosaroxin 
(formerly voreloxin) is a first-in-class anticancer 
quinolone derivative that intercalates DNA and inhibits 
topoisomerase II, inducing site-selective double-strand 
breaks (DSB), G2 arrest and apoptosis. Homologous 
recombination repair (HRR) is critical for recovery 
from DNA damage induced by both agents, identifying 
the potential to clinically exploit synthetic lethality 
[109]. Depletion of POLQ (DNA polymerase theta) 
renders tumor cells more sensitive to radiotherapy 
without effecting normal tissues, providing ways to 
increase therapeutic window [110]. Mycoplasma is also 
a target for cancer prevention [111] and therapy [112]. 
Among additional targets is activating transcription 
factor 5 (ATF5), an anti-apoptotic protein that is highly 
expressed in malignant glioma but not normal brain 
tissues, and is essential for glioma cell survival [113]. 
There were several developments in targeting p53 and 
its cousins, p73 and p63 [114-121]. Nutlin-3a is a non-
genotoxic inducer of p53 and causes the transcription-
independent mitochondrial p53 program of nutlin-
induced apoptosis in tumor cells [122] p53-dependent 
inhibition of TrxR1 contributes to the tumor-specific 
induction of apoptosis by RITA [123]. A new 
therapeutic basis for treating Li-Fraumeni syndrome 
breast tumors expressing mutated p53 has been 
suggested [124]. Importang breakthrough was the 
development of curaxins: anticancer compounds that 
simultaneously suppress NF-kB and activate p53 by 
targeting FACT [30, 125, 126]. 
 
There was continued development of new ways of drug 
delivery including liposomes and nanoparticles [91, 
127-130]. There are several highly innovative strategies 
such as targeting tumors with Salmonella Typhimurium 
[131-133] and use of low-level doses of [(32)P]ATP to 
inhibit tumor growth  [134]. Several cancer treatment 
approaches, such as proteasome inhibitor Bortezomib 
and hsp90 inhibitor geldanamycin, involve 
accumulation of misfolded proteins creating proteotoxic 
stress. Low efficacy of these therapies is likely due to 
the protective effects of heat shock response (HSR) 
induced in treated cells, making this pathway an 
attractive target for pharmacological suppression. It was 
shown that the anti-malaria drugs quinacrine prevented 
HSR in cancer cells. Quinacrine did not affect protein 
synthesis, but rather suppressed inducible HSF1-
dependent transcription of the hsp70 gene. A 
combination of non-toxic concentrations of quinacrine 
and proteotoxic stress inducers resulted in rapid induction 
of apoptosis in cancer cells. Therefore, quinacrine, a  
non-toxic drug long used for treatment of malaria, has  
significant clinical potential in cancer therapy [80, 135-
137]. Another example is proteotoxic stress targeted 
therapy (PSTT), where the induction of protein 
misfolding enhances the antitumor effect of the 
proteasome inhibitor Bortezomib [138]. Also it was 
shown that hypoxia enhances the replication of oncolytic 
herpes simplex virus in p53- breast cancer cells [139]. 
 
Aerobic glycolysis, characterized by high glucose 
uptake, low oxygen consumption and elevated 
production of lactate, is associated with a survival 
advantage and is a hallmark of cancer. Targeting key 
metabolic enzymes involved in glycolysis may provide 
a novel therapeutic approach [140-145]. 
 
There was also further development of the concept of 
synthetic lethality [146-149]. Synthetic lethal 
interactions between mutated oncogenes/tumor 
suppressor genes and molecules involved in DNA 
damage signaling and repair can be therapeutically 
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exploited to preferentially kill tumor cells [150]. As 
another example of synthetic lethality, activation of 
mTOR by targeting TSC2 is toxic in cancer cells 
lacking Rb [151, 152]. 
 
Intriguingly, activation of mTOR converts arrest caused 
by p53 into senescence [153-156]. And vice versa, 
inhibition of mTOR allows arrested cells to avoid 
senescence, remaining merely quiescent. This is in 
agreement with the notion that mTOR is involved in 
aging and aging and age-related diseases [157, 158]. 
 
There was also further development of the concept of 
protection of normal cells [159]. Pre-treatment with low 
doses of actinomycin D, a clinically-approved drug and 
potent p53 activator, before adding the aurora kinase 
inhibitor VX-680 protected normal fibroblasts from 
polyploidy and nuclear morphology abnormalities 
induced by VX-680 [160]. Similarly, normal cells could 
be protected from cytotoxic chemotherapy by nutlin-3a, 
actinomycin, rapamycin and metformin alone or in 
combinations [161-163]. Several other strategies to 
protect normal cells are under development [164-166]. 
 
As a side effect, CPT-11 can cause severe diarrhea 
caused by symbiotic bacterial beta-glucuronidases that 
reactivate the drug in the gut. The strategy was 
suggested to target these enzymes without killing the 
bacteria essential for human health. Bacterial beta-
glucuronidase inhibitors were identified, which have no 
effect on the orthologous mammalian enzyme. 
Inhibitors were effective against the enzyme target in 
living bacteria, but did not kill the bacteria or harm 
mammalian cells. Oral administration of an inhibitor 
protected mice from CPT-11-induced toxicity [167].In 
another study, transgenic mice overexpressing p53 were 
protected from the gastrointestinal syndrome after 
irradiation. This suggests that the gastrointestinal 
syndrome is caused by the death of gastrointestinal 
epithelial cells and that these epithelial cells die by a 
mechanism that is regulated by p53 but independent of 
apoptosis  [168]. While inhibition of Notch1 plus 
Notch2 causes severe intestinal toxicity, therapeutic 
antibody targeting of individual Notch receptors avoids 
this effect, demonstrating a clear advantage over pan-
Notch inhibitors [169]. Interestingly, chromosomal 
instability (CIN) is associated with intrinsic resistance 
to taxanes, acquired multidrug resistance and poor 
prognosis.  In contrast, platinum agents may specifically 
target CIN cancers [170]. 
 
In addition to quinacrine, other well known, non-toxic 
drugs are under re-development for cancer therapy. One 
of them is metformin, an anti-diabetic drug [171-186]. 
Several research groups observed that breast cancer 
patients receiving beta-blockers for hypertension had 
reduced metastasis and improved clinical outcome. 
Medical records revealed that beta-blocker treated 
patients showed a significant reduction in metastasis 
development, tumor recurrence, and longer disease free 
interval after surgery. In addition, there was a reduced 
risk of metastasis and a reduction in breast cancer 
mortality [187-189]. This finding was further confirmed 
[190-192]. Another advance is to use of Angiotensin II 
type 1 receptor blockers in ER-positive and ERBB2-
negative breast cancer cases [193]. 
 
 
Thus there have been significant advances to the 
targeting of various cancers, both with selective 
inhibitors and with drugs such as rapamycin and 
metformin which have been used to treat organ 
transplant patients and diabetics respectively. Further 
studies will continue to evaluate the effectiveness of 
targeting the various pathways mentioned in this review 
with signal transduction inhibitors, natural products, 
chemotherapeutic drugs and drugs used for different 
medial purposes either by themselves or in various 
intelligent combinations based on the knowledge of the 
critical signal transduction pathways altered in the 
particular cancer cell. 
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